Cutaneous Lupus Erythematosus-Pipeline Review 2021

Cutaneous Lupus Erythematosus- Pipeline Review

Lupus erythematosus (LE) is a type of autoimmune disorder and connective tissue disease that can infects one or several organs. Circulating autoantibodies and immune complexes are pathogenic and occurs due to loss of normal immune tolerance. The clinical characteristics of LE are extremely variable. LE virtually mainly affects the skin to some extent. Cutaneous LE includes various chronic and relapsing LE-specific and LE-nonspecific inflammatory situations. Cutaneous LE most rarely affects young to middle-aged adult women (aged 20–50 years). Whereas, children, the elderly, and males are mostly affected.

Important influencing factors for cutaneous LE include:

• Female sex
• Genes: ≥ 25 risk loci have been recognized, and there are HLA associations
• Skin of color

Drug-induced subacute cutaneous LE

Drug-induced lupus are associated with more than 100 drugs and mostly present with subacute cutaneous LE. They include:

• Terbinafine
• Tumour necrosis factor-alpha (TNF-α) inhibitors (biologics)
• Anticonvulsants
• Proton-pump inhibitors.

Pharmaceutical companies are focusing on launching drugs to treat cutaneous lupus erythematosus. For instance, on December 2019, Biogen declared positive results of Phase 2 study for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). The Phase 2 LILAC aim is to undergo primary endpoints, representing statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placebo.

Approximately 70% of pipeline drugs for Cutaneous Lupus Erythematosus are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Cutaneous Lupus Erythematosus.

Report Description

The report on Cutaneous Lupus Erythematosus- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Cutaneous Lupus Erythematosus. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Cutaneous Lupus Erythematosus (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline